Emil Ramsø Kyvsgaard

Emil Ramsø Kyvsgaard serves as a Guest Researcher in the Grønbæk Group at the Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark. His research focuses on clinical hematology and oncology, specifically investigating immunotherapy mechanisms and treatment outcomes in B-cell lymphoma patients.

His primary research interests span hematology, oncology, and immunotherapy, with concentrated expertise in bispecific antibody therapies (particularly CD20xCD3), molecular biomarkers of therapy resistance, NOTCH1 mutations, CD20 expression dynamics, and infection outcomes in immunocompromised lymphoma patients. Current work bridges laboratory findings with clinical applications to optimize lymphoma treatment protocols.

Analysis of his 2023-2025 publications reveals a consistent focus on translational lymphoma research, emphasizing real-world treatment efficacy, resistance mechanisms, and patient safety during immunotherapy. Key trends include molecular characterization of resistance biomarkers, survival analysis in CD20-targeted therapies, and infection risk assessment in novel immunotherapeutic regimens.

Dr. Kyvsgaard actively collaborates within the Grønbæk Group at BRIC, University of Copenhagen, working alongside principal investigator Kirsten Grønbæk and international researchers including Martin Hutchings and Christian Ulrik Nielsen. His work demonstrates significant engagement with clinical trial data and molecular diagnostics in hematological malignancies.